Skip to main content

Week In Review: Abbisko Out-Licenses Rights To Precision NSCLC Medicine For $188 Million

Abbisko Therapeutics out-licensed Greater China rights to a pre-clinical EGFR-TKI candidate for NSCLC to Allist Pharma in a $188 million deal. Also, Chipscreen Bio acquired greater China rights to a bispecific immunotherapy from Eucure Biopharma.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.